Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial

BACKGROUND: Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates. OBJECTIVE: To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT random...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnston, Thomas J., Shaw, Greg L., Lamb, Alastair D., Parashar, Deepak, Greenberg, David, Xiong, Tengbin, Edwards, Alison L., Gnanapragasam, Vincent, Holding, Peter, Herbert, Phillipa, Davis, Michael, Mizielinsk, Elizabeth, Lane, J. Athene, Oxley, Jon, Robinson, Mary, Mason, Malcolm, Staffurth, John, Bollina, Prasad, Catto, James, Doble, Andrew, Doherty, Alan, Gillatt, David, Kockelbergh, Roger, Kynaston, Howard, Prescott, Steve, Paul, Alan, Powell, Philip, Rosario, Derek, Rowe, Edward, Donovan, Jenny L., Hamdy, Freddie C., Neal, David E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2017
Materias:
Platinum Priority – Prostate Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289293/
https://www.ncbi.nlm.nih.gov/pubmed/27720537
http://dx.doi.org/10.1016/j.eururo.2016.09.040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289293/
https://www.ncbi.nlm.nih.gov/pubmed/27720537
http://dx.doi.org/10.1016/j.eururo.2016.09.040

Ejemplares similares